Clinical significance of enlarged lateral pelvic lymph nodes before and after preoperative chemoradiotherapy for rectal cancer

Inoue,Yasuhiro; Saigusa,Susumu; Hiro,Junichiro; Toiyama,Yuji; Araki,Toshimitsu; Tanaka,Koji; Mohri,Yaushiko; Kusunoki,Masato

doi:10.3892/mco.2016.855

Clinical significance of enlarged lateral pelvic lymph nodes before and after preoperative chemoradiotherapy for rectal cancer

Authors:
- Yasuhiro Inoue
- Susumu Saigusa
- Junichiro Hiro
- Yuji Toiyama
- Toshimitsu Araki
- Koji Tanaka
- Yaushiko Mohri
- Masato Kusunoki
View Affiliations

Affiliations: Division of Reparative Medicine, Department of Gastrointestinal and Pediatric Surgery, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: April 8, 2016 https://doi.org/10.3892/mco.2016.855
Pages: 994-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preoperative chemoradiotherapy (CRT) with total mesorectal excision (TME) is the widely accepted treatment for rectal cancer (rc) in Western countries. However, there remains controversy as to whether preoperative CRT is useful in tumors that extend beyond the mesorectum, including metastasis to the lateral pelvic lymph nodes (LPLN). The aim of this study was to assess the prognostic significance of LPLN enlargement in patients with RC who receive preoperative CRT followed by TME without LPLN dissection. We evaluated the prognostic effect of radiographic LPLN enlargement before and after CRT, as well as the patients' clinicopathological and genetic profiles. Of the 104 patients investigated, pretreatment imaging identified 19 (18%) as LPLN‑positive (>7 mm in diameter). Of these 19 patients, 7 (37%) exhibited LPLN downsizing to <7 mm following CRT. The median follow‑up period was 52 months. The 5‑year cancer‑specific survival (CSs) or relapse‑free survival (RFS) did not differ significantly between patients who did and those who did not have positive LPLN on pretreatment imaging. However, LPLN that remained positive after CRT were significantly associated with poorer 5‑year CSS (73 vs. 84%, respectively; P=0.0052) and RFS (32 vs. 78%, respectively; P=0.0264). None of the patients whose LPLN were downsized to <7 mm following CRT developed recurrence; however, those with positive LPLN after CRT had a 55% higher recurrence rate, characterized by delayed local recurrence, a pattern that may be affected by certain chemokines. In conclusion, changes in initially positive LPLN (>7 mm) may predict the prognosis of patients with RC who receive preoperative CRT‑TME. LPLN positivity after CRT was associated with shorter CSs and RFS. Strategies to improve patient survival may include selective LPLN dissection or more aggressive multimodality therapy.

View Figures

View References

1	Ueno M, Oya M, Azekura K, Yamaguchi T and Muto T: Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. Br J Surg. 92:756–763. 2005. View Article : Google Scholar : PubMed/NCBI
2	Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, Shirouzu K and Muto T: Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum. 49:1663–1672. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ueno H, Mochizuki H, Hashiguchi Y, Ishiguro M, Miyoshi M, Kajiwara Y, Sato T, Shimazaki H and Hase K: Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection. Ann Surg. 245:80–87. 2007. View Article : Google Scholar : PubMed/NCBI
4	Kobayashi H, Mochizuki H, Kato T, Mori T, Kameoka S, Shirouzu K and Sugihara K: Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection. Dis Colon Rectum. 52:567–576. 2009. View Article : Google Scholar : PubMed/NCBI
5	Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T and Sugihara K: Japanese Society for Cancer of the Colon and Rectum: Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: Is it regional or distant disease? Ann Surg. 255:1129–1134. 2012. View Article : Google Scholar : PubMed/NCBI
6	Watanabe T, Tsurita G, Muto T, Sawada T, Sunouchi K, Higuchi Y, Komuro Y, Kanazawa T, Iijima T, Miyaki M and Nagawa H: Extended lymphadenectomy and preoperative radiotherapy for lower rectal cancers. Surgery. 132:27–33. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yano H, Saito Y, Takeshita E, Miyake O and Ishizuka N: Prediction of lateral pelvic node involvement in low rectal cancer by conventional computed tomography. Br J Surg. 94:1014–1019. 2007. View Article : Google Scholar : PubMed/NCBI
8	Dharmarajan S, Shuai D, Fajardo AD, Birnbaum EH, Hunt SR, Mutch MG, Fleshman JW and Lin AY: Clinically enlarged lateral pelvic lymph nodes do not influence prognosis after neoadjuvant therapy and TME in stage III rectal cancer. J Gastrointest Surg. 15:1368–1374. 2011. View Article : Google Scholar : PubMed/NCBI
9	Akiyoshi T, Ueno M, Matsueda K, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Unno T, Kano A, Kuroyanagi H, et al: Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. Ann Surg Oncol. 21:189–196. 2014. View Article : Google Scholar : PubMed/NCBI
10	Lim SB, Yu CS, Kim CW, Yoon YS, Park SH, Kim TW, Kim JH and Kim JC: Clinical implication of additional selective lateral lymph node excision in patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy. Int J Colorectal Dis. 28:1667–1674. 2013. View Article : Google Scholar : PubMed/NCBI
11	Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. (2nd English). (Tokyo). Kanehara & Co. Ltd. 7–10. 2009.
12	Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 61:1029–1037. 2001.PubMed/NCBI
13	Inoue Y, Okigami M, Kawamoto A, Okugawa Y, Hiro J, Saigusa S, Toiyama Y, Tanaka K, Mohri Y and Kusunoki M: Phase I study of 5-fluorouracil, leucovorin and bevacizumab in combination with radiation therapy in patients with locally advanced rectal cancer. Mol Clin Oncol. 1:511–516. 2013.PubMed/NCBI
14	Saigusa S, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, Okugawa Y, Hiro J, Inoue Y, Uchida K, Mohri Y and Kusunoki M: Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Oncol Rep. 28:855–861. 2012.PubMed/NCBI
15	Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Inoue Y, Miki C and Kusunoki M: Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. Ann Surg Oncol. 17:2051–2058. 2010. View Article : Google Scholar : PubMed/NCBI
16	Moriya Y, Sugihara K, Akasu T and Fujita S: Importance of extende lymphadenectomy with lateral node dissection for advanced lower rectal cancer. World J Surg. 21:728–732. 1997. View Article : Google Scholar : PubMed/NCBI
17	Sugihara K, Moriya Y, Akasu T and Fujita S: Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome. Cancer. 78:1871–1880. 1996. View Article : Google Scholar : PubMed/NCBI
18	Beyond TME Collaborative: Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg. 100:1009–1014. 2013. View Article : Google Scholar : PubMed/NCBI
19	Benson AB III, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, et al: Rectal cancer. J Natl Compr Canc Netw. 10:1528–1564. 2012.PubMed/NCBI
20	Quadros CA, Falcão MF, Carvalho ME and Ladeia PA: Metastases to retroperitoneal or lateral pelvic lymph nodes indicated unfavorable survival and high pelvic recurrence rates in a cohort of 102 patients with low rectal adenocarcinoma. J Surg Oncol. 106:653–658. 2012. View Article : Google Scholar : PubMed/NCBI
21	Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S and Tosato G: Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 99:2703–2711. 2001. View Article : Google Scholar
22	Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ and Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 23:2744–2753. 2005. View Article : Google Scholar : PubMed/NCBI
24	Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, Nakano K, Itami A, Kawada K, Nagayama S and Sakai Y: Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol. 16:2645–2653. 2009. View Article : Google Scholar : PubMed/NCBI
25	Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, et al: Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res. 12:2795–2803. 2006. View Article : Google Scholar : PubMed/NCBI